Pfizer Finalizes $7B Acquisition of Metsera to Bolster Obesity Pipeline

New York, November 13, 2025 (Business Wire) -- Pfizer completed its purchase of Metsera for $65.60 per share in cash, valuing the company at approximately $7.0 billion, with an additional contingent value right of up to $20.65 per share tied to three clinical and regulatory milestones. The deal adds multiple metabolic assets, including MET-097i, a weekly or monthly GLP-1 RA entering Phase 3, MET-233i, a monthly amylin analog in Phase 1, an oral GLP-1 RA in Phase 1, and additional preclinical hormone programs. Pfizer noted the transaction will be dilutive through 2030, with updated financial guidance to come later in 2025.

Read full article here.